Literature DB >> 20412814

Analysis of camelid antibodies for antivenom development: Neutralisation of venom-induced pathology.

Darren A N Cook1, Timothy Owen, Simon C Wagstaff, Joerg Kinne, Ulrich Wernery, Robert A Harrison.   

Abstract

Camelid IgG has been reported to be less immunogenic, less able to activate the complement cascade and more thermostable than IgG from other mammals, and has the ability to bind antigens that are unreactive with other mammalian IgGs. We are investigating whether these attributes of camelid IgG translate into antivenom with immunological and venom-neutralising efficacy advantages over conventional equine and ovine antivenoms. The objective of this study was to determine the preclinical venom-neutralising effectiveness of IgG from camels immunised with venoms, individually or in combination, of the saw-scaled viper, Echis ocellatus, the puff adder, Bitis arietans and the spitting cobra, Naja nigricollis - the most medically-important snake species in West Africa. Neutralisation of the pathological effects of venoms from E. ocellatus, B. arietans and N. nigricollis by IgG from the venom-immunised camels, or commercial antivenom, was compared using assays of venom lethality (ED(50)), haemorrhage (MHD) and coagulopathy (MCD). The E. ocellatus venom ED(50), MHD and MCD results of the E. ocellatus monospecific camel IgG antivenom were broadly equivalent to comparable ovine (EchiTAbG, MicroPharm Ltd, Wales) and equine (SAIMR Echis, South African Vaccine Producer, South Africa) antivenoms, although the equine antivenom required half the amount of IgG. The B. arietans monospecific camel IgG neutralised the lethal effects of B. arietans venom at one fourth the concentration of the SAIMR polyspecific antivenom (a monospecific B. arietans antivenom is not available). The N. nigricollis camel IgG antivenom was ineffective (at the maximum permitted dose, 100 mul) against the lethal effects of N. nigricollis venom. All the equine polyspecific antivenoms required more than 100 microl to be effective against this venom. The polyspecific camel IgG antivenom, prepared from five camels, was effective against the venom-induced effects of E. ocellatus but not against that of B. arietans and N. nigricollis venoms. No direct correlation was evident between either camel IgG relative avidity or titre and the effectiveness of venom neutralisation in preclinical assays. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20412814     DOI: 10.1016/j.toxicon.2010.04.005

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  9 in total

1.  An analysis of preclinical efficacy testing of antivenoms for sub-Saharan Africa: Inadequate independent scrutiny and poor-quality reporting are barriers to improving snakebite treatment and management.

Authors:  Stuart Ainsworth; Stefanie K Menzies; Nicholas R Casewell; Robert A Harrison
Journal:  PLoS Negl Trop Dis       Date:  2020-08-20

2.  Pre-clinical assays predict pan-African Echis viper efficacy for a species-specific antivenom.

Authors:  Nicholas R Casewell; Darren A N Cook; Simon C Wagstaff; Abdulsalami Nasidi; Nandul Durfa; Wolfgang Wüster; Robert A Harrison
Journal:  PLoS Negl Trop Dis       Date:  2010-10-26

3.  In vitro toxic effects of puff adder (Bitis arietans) venom, and their neutralization by antivenom.

Authors:  Steven Fernandez; Wayne Hodgson; Janeyuth Chaisakul; Rachelle Kornhauser; Nicki Konstantakopoulos; Alexander Ian Smith; Sanjaya Kuruppu
Journal:  Toxins (Basel)       Date:  2014-05-19       Impact factor: 4.546

4.  A comparative study on the equine and camelid antivenoms upon cardiovascular changes induced with Hemiscorpius lepturus venom in rats.

Authors:  Hossein Fatemikia; Mostafa Kamyab; Ali Movahed; Mehdi Sadeghi; Euikyung Kim; Mahdi Behdani; Naser Mohammadpour Dounighi; Mehrnaz Shahrivar; Ramin Seyedian
Journal:  Iran J Basic Med Sci       Date:  2019-12       Impact factor: 2.699

5.  Anti-Metalloprotease P-I Single-Domain Antibodies: Tools for Next-Generation Snakebite Antivenoms.

Authors:  Marcela C S Silva; Soraya S Pereira; Marilia P Gouveia; Marcos B Luiz; Rosa M O Sousa; Anderson M Kayano; Aleff F Francisco; Nidiane D R Prado; Leandro S M Dill; Marcos R M Fontes; Fernando B Zanchi; Rodrigo G Stabeli; Andreimar M Soares; Juliana P Zuliani; Carla F C Fernandes
Journal:  Biomed Res Int       Date:  2022-07-19       Impact factor: 3.246

6.  Preclinical validation of a repurposed metal chelator as an early-intervention therapeutic for hemotoxic snakebite.

Authors:  Laura-Oana Albulescu; Melissa S Hale; Stuart Ainsworth; Jaffer Alsolaiss; Edouard Crittenden; Juan J Calvete; Chloe Evans; Mark C Wilkinson; Robert A Harrison; Jeroen Kool; Nicholas R Casewell
Journal:  Sci Transl Med       Date:  2020-05-06       Impact factor: 17.956

7.  Insufficient Anthrax Lethal Toxin Neutralization Is Associated with Antibody Subclass and Domain Specificity in the Plasma of Anthrax-Vaccinated Individuals.

Authors:  Kenneth Smith; Lori Garman; Kathleen Norris; Jennifer Muther; Angie Duke; Renata J M Engler; Michael R Nelson; Limone C Collins; Christina Spooner; Carla Guthridge; Judith A James
Journal:  Microorganisms       Date:  2021-06-02

8.  In vivo neutralization of α-cobratoxin with high-affinity llama single-domain antibodies (VHHs) and a VHH-Fc antibody.

Authors:  Gabrielle Richard; Ashley J Meyers; Michael D McLean; Mehdi Arbabi-Ghahroudi; Roger MacKenzie; J Christopher Hall
Journal:  PLoS One       Date:  2013-07-22       Impact factor: 3.240

Review 9.  Snakebite: When the Human Touch Becomes a Bad Touch.

Authors:  Bryan G Fry
Journal:  Toxins (Basel)       Date:  2018-04-21       Impact factor: 4.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.